CEO of Progen Co., Ltd.
Former) Yuhan Corp. R&D Strategy Head/Biologics New Drug Division Head/Global New Drug Center Head

• Ph.D., Seoul National University, Bioengineering
• M.S, Chungbuk National University, Microbiology

PG-102 is a first-in-class gut-targeted metabolic biologic designed to move treatment beyond conventional incretin paradigms.

By integrating long-acting GLP-1 activity with the complementary biology of GLP-2 co-agonism, PG-102 is being developed to deliver durable metabolic efficacy with improved metabolic quality, enhanced tolerability, and long-term treatment sustainability.

Unlike conventional CNS-driven approaches focused primarily on appetite suppression, PG-102 aims to restore healthier body composition, improve gastrointestinal tolerability, and reduce the chronic metabolic burden associated with obesity and type 2 diabetes.

The program is advancing into multiple Phase 2b studies focused on monthly maintenance therapy, high-exposure obesity regimens, and metabolically vulnerable populations, including elderly type 2 diabetes.

CEO of Progen Co., Ltd.
Former) CEO, ToolGen Inc.
Former) CEO, MGmed Inc. (Currently Dx&Vx)
Former) CEO, Macrogen Inc.

• B.B.A in Business Administration, Yonsei University

Chief Medical Officer of Progen Co., Ltd.
Former) President and Chairman of the Korean Diabetes Association (KDA)
Former) Professor, Department of Endocrinology, Seoul St. Mary's Hospital
Former) Director, Graduate School, Catholic University
Former) Chairman, Digital Healthcare Special Committee, Presidential Committee on the 4th Industrial Revolution

• M.D-Ph.D., Catholic University, Doctor of Medicine
  (Internal Medicine / Endocrinology & Metabolism Specialist)

Chief Technology Officer of ProGen Co., Ltd.
Former) CEO of SL Metagen Co., Ltd.
Former) Genexine, Inc., Deputy Director of Bio Research Institute / Director of Non-clinical Laboratory

• M.S/Ph.D., Sungkyunkwan University, Pharmacology

Discovery Team Leader of ProGen Co., Ltd.
Former) Research Associate Professor, Medical Research Center, Genomic Medicine Institute, Seoul National University
Former) Research Associate Scientist, Columbia University Medical Center

• Ph.D. in Biochemistry, University of Alabama at Birmingham

• M.S. in Biological Sciences, Seoul National University

Chief Strategic Planning Officer of ProGen Co., Ltd.
Adjunct Professor, College of Pharmacy, Yonsei University
Former) CDO of SL Metagen Co., Ltd.
Former) Senior Researcher of SL Bigen Co., Ltd.

• Ph.D., POSTECH, Life Sciences
• B.S, Johns Hopkins University, Chemical and Biomolecular Engineering

PG-102 Pill is a first-in-class oral GLP-1/GLP-2 dual agonist designed to redefine the potential of oral biologics in metabolic disease.

Enabled by the proprietary RaniPill® platform, the program aims to achieve injectable-like systemic exposure with a once-weekly oral dosing profile.

Unlike conventional daily oral incretins, PG-102 Pill is being developed to deliver durable metabolic efficacy with improved gastrointestinal tolerability, visceral fat targeting, and healthier body composition through GLP-2 co-agonism.

The program has completed Phase 1a evaluation and is advancing into repeat-dose Phase 1b studies in obesity to validate weekly oral biologic feasibility and differentiated metabolic efficacy.

PG-110 is a next-generation musculoskeletal biologic designed to preserve muscle function and metabolic health in obesity and aging-related conditions.

By combining moderated ActRII inhibition with soluble myostatin neutralization, PG-110 is engineered to improve muscle functionality while minimizing liabilities associated with conventional ActRII blockade.

An additional undisclosed metabolic component further expands the therapeutic profile toward broader musculoskeletal health and long-term metabolic resilience.

Unlike conventional muscle-directed approaches focused primarily on muscle mass, PG-110 is being developed to deliver differentiated functional muscle improvement with improved tolerability and chronic treatment feasibility.

The program is currently advancing through preclinical evaluation.

PG-401 is a next-generation bispecific biologic designed to deliver dual-pathway suppression of type 2 inflammation in asthma.

By simultaneously targeting a key upstream initiator of the inflammatory cascade and a downstream amplification pathway, PG-401 aims to achieve broader and more durable inflammatory control beyond conventional single-pathway therapies.

Current lead molecules have demonstrated benchmark-level affinity and potency against both critical nodes in preclinical evaluation.

The program is advancing toward final lead candidate selection and planned preclinical development initiation in 2026.